Please assess the completion status of the following clinical trial:

Trial Title: Methylphenidate Treatment of Attention Deficits in Epilepsy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~1. For participants with seizures:~   * H/o seizures of any cause~  * Subjective cognitive complaints~  * Stable antiepileptic drug doses which are not expected to change during the study~  * Recent normal cardiac auscultation (may be done prior to enrollment by personal physician or study staff)~  * Neurologist's judgement that participant is clinically appropriate for this study~2. For healthy volunteers~   * No history of seizures or other neurological disorders~  * No history of cognitive complaints for any reason (including ADHD)~  * Not on any medications which would interfere w/ cognitive testing~3. English fluency~Exclusion Criteria:~1. IQ~2. History of an adverse reaction to methylphenidate~3. Age \>65 or \<18~4. Personal medical history of~   1. Arrhythmias,~  2. Structural cardiac disease,~  3. Other cardiac abnormality~  4. Uncontrolled hypertension (\>150/95) during study. For those with BP \>140/90 \& \<150/95, they will be monitored during the study and refer them for treatment if their BP remains elevated throughout the study.~  5. Uncontrolled tachycardia during study~  6. Progressive neurological disorders which may interfere w/ cognition for reasons other than seizures~  7. Glaucoma~  8. Other medical or neurological illnesses or symptoms which may interfere with cognition or medication (e.g., severe liver or renal disease, active infections, etc), or which make use of the medication inappropriate (e.g., severe agitation/anxiety).~  9. Intellectual disability sufficient to render a participant unable to consent~  10. Status epilepticus within the last year~  11. Neurosurgery which would be expected to interfere with study tasks within the last 6 months.~5. Substance use history~   1. Met criteria for substance use disorder within the past year~  2. Active illicit substance use~  3. Alcohol use meeting criteria for substance abuse~  4. Unwillingness to abstain from alcohol w/in 24 hours of testing~6. Personal psychiatric history~   1. History of a primary psychotic disorder, such as schizophrenia, or mania.~  2. History of suicide attempts within the last year~  3. Active suicidality~7. Severe cognitive impairments (e.g. aphasia) which render a participant unable to consent~8. Currently receiving medications which would be expected to interfere with the study tasks, if they cannot be held for study visits;~9. Pregnancy or active breastfeeding;~10. Women of childbearing potential who are sexually active and not willing or able to use a contraceptive strategy during the course of the study.~11. Any other factor which may interfere w/ a participant's ability to consent or to complete the required cognitive tasks, or may significantly interfere with their performance on the required tests~12. Concomitant use of an MAOI (if receiving methylphenidate during this study), or use of an MAOI within the last 14 days prior to receiving methylphenidate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Controls (Type: NO_INTERVENTION): Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.~Healthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion.
- Participants With Epilepsy (Open-label) (Type: EXPERIMENTAL): Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After a four week treatment trial, their scores on the batteries and questionnaires were again assessed.
- 10mg, 20mg, Then Placebo (Double-blind) (Type: EXPERIMENTAL): Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.
- 10mg, Placebo, Then 20mg (Double-blind) (Type: EXPERIMENTAL): Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.
- Placebo, 20mg, Then 10mg (Double-blind) (Type: EXPERIMENTAL): Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.
- Placebo, 10mg, Then 20mg (Double-blind) (Type: EXPERIMENTAL): Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.
- 20mg, Placebo, Then 10mg (Double-blind) (Type: EXPERIMENTAL): Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.
- 20mg, 10mg, Then Placebo - Double-blind (Type: EXPERIMENTAL): Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time.
- 40mg, 20mg, Then Placebo (One Participant) (Type: EXPERIMENTAL): This study was originally intended to use 40mg, 20mg, and placebo doses rather than 20mg, 10mg, and placebo. This individual developed tachycardia (see adverse events) on the 40mg dose, and was withdrawn from the double-blind portion as a result. We removed the 40mg doses from this study and replaced them with 10mg doses. No other participant received a 40mg dose. This participant rejoined the open-label portion after consultation with his PCP due to significant perceived benefit from the MPH dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).